Form 4: Regeneron Executive George Yancopoulos Reports Stock Transfers
SEC Form 4 Filing
George Yancopoulos, a Director, Bd. Co-Chair, President & CSO of Regeneron Pharmaceuticals, reported the disposition of shares to a GRAT and acquisition of shares by his children.
Summary
- On April 29, 2024, George Yancopoulos, a Director, Bd. Co-Chair, President & CSO of Regeneron Pharmaceuticals, reported transactions involving Regeneron common stock.
- He disposed of 36,296 shares indirectly through a 2022 GRAT.
- He acquired 18,148 shares indirectly for his children.
- Yancopoulos directly owns 886,383 shares of common stock.
- He indirectly owns 5,903 shares through a 401(k) plan, 180,000 shares through a trust for children, and 158,410 shares through a 2022 GRAT II.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing stock transactions, with neutral sentiment.
Industry Context
This filing is a routine disclosure related to executive stock transactions and doesn't necessarily indicate a change in the company's outlook or performance.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the change in ownership, but the overall impact is likely minimal.
Key Dates
| Date | Description |
|---|---|
| 04/29/2024 | Date of stock transactions (disposition to GRAT and acquisition by children) |
| 05/01/2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.